Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology. These new findings suggest triglyceride-rich LDL particles could be a novel diagnostic marker for ASCAD and could also open up potential novel treatment targets for the condition.
“This landmark result clearly demonstrates the power of causal AI and Digital Twins to reveal the hidden circuitry of cardiovascular disease from large-scale multi-omic data” said Colin Hill, CEO and co-founder of Aitia.
Read the full article here.
Credit: wildpixel/Getty Images